JFGIW
PMCB icon

Johnson Financial Group Inc (Wisconsin)’s PharmaCyte Biotech PMCB Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 891

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Johnson Financial Group Inc (Wisconsin)'s PMCB Position: Q1 2026 in Review

Johnson Financial Group Inc (Wisconsin) opened a new position in PharmaCyte Biotech (PMCB) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #891 among its holdings.

32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Johnson Financial Group Inc (Wisconsin) held 1 share of PharmaCyte Biotech worth $1 as of Q1 2026.
  • PharmaCyte Biotech was a new Johnson Financial Group Inc (Wisconsin) position in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Johnson Financial Group Inc (Wisconsin)'s portfolio in Q1 2026, its #891 holding.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2026, filed 7 May 2026.